Lineage Cell Therapeutics, Inc. (LCTX) Gross margin 2016–2023
Lineage Cell Therapeutics, Inc. (LCTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
92.5%FY2023 · since FY2016: 94.0% → 92.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | 92.5% | -2.6 pp |
| FY2022 | 95.0% | +27.9 pp |
| FY2021 | 67.2% | -11.8 pp |
| FY2020 | 78.9% | -9.4 pp |
| FY2019 | 88.3% | -5.7 pp |
| FY2018 | 93.9% | -1.2 pp |
| FY2017 | 95.1% | +1.2 pp |
| FY2016 | 94.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice